Loading...
NPI 1295929511 · Reno, NV · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Arshad Khanani is a ophthalmology physician provider located in Reno, Nevada. This profile covers 18 Medicare and 3 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Arshad Khanani |
| Address | 950 Ryland St |
| City | Reno |
| State | NV |
| ZIP | 89502 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | August 29, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $6.5M |
| Medicaid | $17.6K |
This provider’s Medicare business is highly concentrated in intravitreal biologic administration: J2777 (faricimab) alone generated $4.1M in Medicare revenue and represents 62.4% of the provider’s Medicare revenue, and the top three Medicare codes together account for 83.9% of Medicare revenue. The dollar mix (J2777, J2778, J0178) and high claim counts indicate an operational model centered on frequent in‑office injection visits rather than primarily surgical procedures.
The overall payer scale is lopsided: lifetime Medicare revenue is $6.5M versus total Medicaid revenue of $17.6K, so the practice is effectively Medicare‑driven. Medicaid billing exists but is numerically negligible relative to Medicare, making the practice single‑payer dominant in practical terms.
National competitive standing for faricimab administration is extreme: J2777 ranks #8 of 2039 providers nationally (100th percentile; extreme outlier), signaling extraordinarily high national volume for that specific drug. The practice also shows extreme or notably above‑typical national volume on ancillary retina services—92134 ranks #58 of 26868 (100th percentile; extreme outlier), 92014 ranks #254 of 35415 (99th percentile; extreme outlier), and 67028 ranks #79 of 4255 (98th percentile; notably above typical national volume)—which together indicate a high‑throughput retina/injection clinic.
Not all high‑value biologics show the same dominance: J2778 (ranibizumab) produced $733.9K (11.2% of Medicare revenue) and ranks #64 of 1208 (95th percentile; typical, unremarkable volume), while J0178 (aflibercept) produced $676.4K (10.3% of Medicare revenue) and ranks #1278 of 3204 (60th percentile; typical, unremarkable volume). This pattern suggests the provider’s exceptional Medicare footprint is concentrated on faricimab (J2777) more than on other anti‑VEGF agents.
Medicaid activity is limited and modest within state peers: the top three Medicaid codes account for 100.0% of Medicaid revenue, with 92134 contributing $8.3K (47.0% of Medicaid revenue) and ranking #23 of 40 in‑state (44th percentile; typical). 67028 contributed $6.2K (35.1% of Medicaid revenue) and ranks #12 of 13 in‑state (8th percentile; typical), while 92014 contributed $3.2K (18.0% of Medicaid revenue) and ranks #283 of 326 in‑state (13th percentile; typical). These ranks show the provider is not a major Medicaid retina/injection provider in Nevada.
Operational throughput is supported by high diagnostic and exam volumes that align with an injection‑centric practice: 92134 appears with 4.8K Medicare claims and $149.1K revenue (2.3% of Medicare revenue), and exam codes such as 92014 (2K claims, $174.1K; 2.7% of Medicare revenue) and 92012 (960 claims, $67.2K; 1.0% of Medicare revenue) are prominent. The combination of high volumes for imaging and established‑patient exams indicates a workflow optimized for repeated visits and monitoring of retinal disease.
The provider’s procedure mix includes both medical injections and some surgical retinal procedures: 67028 (intravitreal injection as an isolated procedure) shows 3.2K Medicare claims and $317.3K revenue, while surgical codes such as 67042 appear at much lower volume (19 claims, $16.5K). This supports a service line that emphasizes office‑based intravitreal therapy with occasional surgical interventions.
The provider has an established NPI history, enumerated 2007-08-29 (~19 years ago), indicating long tenure in the market. Coupled with the concentrated Medicare volume and the extreme national ranking on key retina/injection services, the data point to a stable, mature practice with a specialty focus on high‑volume anti‑VEGF and retina care primarily reimbursed by Medicare.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
18 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 140,940 | $30 | $4.1M |
| J2778 | Injection, ranibizumab, 0.1 mg | 4,170 | $180 | $733.9K |
| J0178 | Injection, aflibercept, 1 mg | 1,010 | $670 | $676.4K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 3,210 | $100 | $317.3K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 1,980 | $90 | $174.1K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 4,810 | $30 | $149.1K |
| J3590 | Unclassified biologics | 60 | $2,150 | $131.1K |
| J2779 | Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg | 1,500 | $60 | $96K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 960 | $70 | $67.2K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 360 | $150 | $55K |
Showing 1–10 of 18
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 18 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
18 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 9 | 20 | 830 | $690 | $671.6K |
| J2777 | 1 | 10 | 7,020 | $30 | $616.8K |
| J2778 | 1 | 10 | 660 | $180 | $249.6K |
| J3590 | 3 | 10 | 90 | $2,050 | $233.8K |
| J2779 | 1 | 10 | 1,500 | $60 | $96K |
| 67028 | 1 | 30 | 670 | $90 | $72.3K |
| J7312 | 4 | 10 | 380 | $160 | $68.5K |
| 67042 | 3 | 10 | 20 | $1,090 | $20.7K |
| J9035 | 21 | 20 | 230 | $50 | $15.6K |
| 92014 | 2 | 290 | 90 | $80 | $15.2K |
Showing 1–10 of 18
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 160 | $50 | $8.3K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 40 | $150 | $6.2K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 20 | $130 | $3.2K |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
3 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 12 | 10 | 140 | $50 | $117.6K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 283 | 330 | 240 | $60 | $55.1K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 23 | 40 | 210 | $20 | $47.3K |
Other providers in the same ZIP code as Arshad Khanani, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.